Pharsight

Drugs that contain Tafamidis

1. Vyndamax patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7214695 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Dec, 2024

(9 months from now)

US9770441 FOLDRX PHARMS Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
Aug, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214696 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Dec, 2024

(9 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 3, 2024
Orphan Drug Exclusivity (ODE) May 3, 2026

NCE-1 date: 2023-05-04

Market Authorisation Date: 03 May, 2019

Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)

Dosage: CAPSULE;ORAL

How can I launch a generic of VYNDAMAX before it's drug patent expiration?
More Information on Dosage

VYNDAMAX family patents

Family Patents